ArticleFrontiers in pharmacology2021

Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting.

Yueh-Ting Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.